HDAC11 and myeloid sarcoma: In the current study, we investigated this hypothesis and found that HDAC11 KO mice have fewer clinical disease symptoms, less demyelination, and less CNS immune cell infiltration in the chronic progressive disease phase of EAE, a mouse model of MS.